+ T cells do not require intrinsic type I IFN signals in response to combined TLR/anti-CD40 vaccination. Rather, the CD4 response is dependent on the expression of type I IFNR (IFNaR) on innate cells. Further, we find that dendritic cell (DC) expression of the TNF superfamily member OX40 ligand was dependent on type I IFN signaling in the DC, resulting in a reduced CD4 + T cell response that could be substantially rescued by an agonistic Ab to the receptor OX40. Taken together, we show that the IFNaR dependence of the CD4 + T cell response is accounted for exclusively by defects in DC activation. The
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T he type I IFN cytokine family is vitally important in providing resistance to viral infections and plays a unique role among cytokines by bridging innate and adaptive immunity (1) . The marked antiviral effects of type I IFN make it clinically useful as an adjuvant to ribavirin as a treatment for hepatitis C virus infection (1, 2) . Furthermore, individuals lacking key intermediates both upstream and downstream of type I IFN signaling succumb to normally nonlethal viral infection (3, 4) . Thus, understanding type I IFN biology holds the promise of better understanding human immunity.
In the periphery, type I IFN signaling induces infected cells and bystanders to adopt an antiviral state (5) mediated by intracellular factors such as protein kinase R, Mx1, and others and characterized by reduced protein synthesis, which limits viral replication (1) . Release of type I IFN in the context of infection (6) , as well as release of byproducts of infection such as dsRNA liberated from lysed cells, leads to the activation of innate cells (7) . Activation of peripheral innate cells such as dendritic cells (DC) by type I IFN leads to the trafficking of these cells to draining lymph nodes (8, 9) . There, DC are autoenhanced by type I IFN (10) to present Ags they may have carried from the periphery in the context of costimulation to naive, primary T cells (10, 11) . The culmination of type I IFN induction is thus the initiation of an adaptive, antiviral, immune response.
Although a picture of the role of type I IFN signaling for DC at various points in the in vitro innate immune response has been developed (10, 11) , the function of type I IFN on DC activation has only recently been explored in vivo (8, 9, 12) . IFN-dependent DC activation has been reported as required for vaccine adjuvant efficacy in other model systems (13) , and it was recently shown that DC-intrinsic sensing of type I IFN was necessary for activation by the TLR agonist polyinosinic-polycytidylic acid (polyI:C) (12) . Given the role of DCs in the initiation of adaptive immunity (14) (15) (16) , it could be expected that defects in DC activation would be a dominant hindrance to the generation of adaptive responses in the absence of type I IFN signals. However, there is a body of literature to suggest that type I IFNs can also have broad, direct effects on responding adaptive immune cells, in particular CD4 + T cells (12, (17) (18) (19) (20) (21) (22) (23) . Thus, it is presently unknown to what extent failure of adaptive immune responses in the absence of type I IFN are attributable to defects in priming DC and which are due to defects in direct signals to T cells. These parameters are particularly important to establish for the purposes of vaccine development, as many of the adjuvants currently being explored have type I IFN induction as a significant contributor to vaccine efficacy (24) .
We have previously shown that combined agonists for TLRs and CD40 (the anti-CD40 Ab FGK4.5) synergistically promote CD8 + T cell responses (25) . Furthermore, CD8 + responses to combined polyI:C and anti-CD40 (polyI:C/CD40) were dependent on the type I IFNR IFNaR1 (IFNaR) (25) . Our experience with CD4 + T cells revealed that they could also be synergistically activated by polyI:C/CD40 (26) and that the activation of CD4 + T cells by polyI:C/CD40 depended upon signals through the TNF superfamily member OX40 ligand (OX40L). However, it remained unknown whether CD4 + T cells activated by polyI:C/CD40 were similarly dependent on signals through IFNaR. Unlike CD4 + T cells, CD8 + T cells require DCs to take up exogenous Ag to be processed and cross-presented on MHC class I (MHC-I), a pathway dependent on type I IFN (9) . Furthermore, whereas a role for type I IFN in CD4 + T cell responses to polyI:C has been established (12) , it was unknown whether the addition of a CD40 agonist would abolish the dependence of polyI:C responses on type I IFN.
We set out to address the role of type I IFN in CD4 + T cell responses initiated by polyI:C/CD40 and confirmed that type I IFN is necessary for CD4 + T cell priming. To our surprise, we found that secondary CD4 + T cell responses were, unlike primary responses, relatively intact in IFN-aR-deficient (IFNaRKO) mice. This suggested that Ag-experienced CD4 + T cells were qualitatively different from naive CD4 + T cells and that the IFN dependency was unlikely due to direct IFN stimulation of the T cell. Indeed, the use of mixed bone marrow chimeras revealed that Rag1 2/2 bone marrow could rescue CD4 + T cell responses in otherwise IFNaRKO mice, demonstrating a role for IFNaR on innate, but not adaptive, cells. We further showed that polyI:C/ CD40-stimulated IFNaRKO DCs had very low expression of OX40L, and restoration of OX40 signals using an agonistic Ab in IFNaRKO mice enhances CD4
+ , but not CD8 + , T cell priming.
Materials and Methods

Mice
Six-to 8-wk-old female C57BL/6 mice were obtained through the National 
Immunizations, depletions, and Ab blockade
Unless indicated otherwise, mice were immunized i.p. with 500 mg whole chicken OVA protein (Sigma-Aldrich, St. Louis, MO), 100 mg Ea-derived 2W1S peptide (EAWGALANWAVDSA; custom synthesized by Pi Proteomics, Huntsville, AL) (27), 50 mg CD40 agonist Ab (clone FGK4.5; BioXCell, West Lebanon, NH), and 50 mg polyI:C (Amersham Biosciences/GE Healthcare, Piscataway, NJ). All vaccinations were prepared by mixing each component together in PBS and injected in 200 ml. PolyI:C was stored in frozen aliquots in PBS at 220˚C and reconstituted prior to injection by melting at 56˚C for 10 min and then allowing the solution to cool to room temperature to limit concatamerization. All reagents were found to contain minimal LPS content by Limulus amebocyte assay (Lonza, Walkersville, MD). Blocking Ab for OX40L (RM134L) and agonistic anti-OX40 (OX86) were obtained from BioXCell. OX40L blockade was facilitated by i.p. injection of 250 mg RM134L in PBS on days 21 and 0 relative to immunization. On day 0, blocking Abs were mixed with prepared vaccines, and both were delivered in a single injection. For OX40 agonist administration, 250 mg OX86 in PBS were mixed with prepared vaccine on day 0 and given together as a single injection. For experiments involving footpad immunization, mice were anesthetized with isofluorane and injected with 50 ml PBS containing 40 mg polyI:C, 40 mg FGK4.5, and 50 mg OVA protein.
Flow cytometry
For T cell assays, mice were sacrificed 7 d post-primary immunization or 5 d post-boost immunization, peripheral blood was harvested from the abdominal aorta, and spleens were harvested and minced with forceps in HBSS containing 5 mM EDTA. Single-cell suspensions were made by passing minced spleens through nylon mesh strainers. RBCs were lysed in peripheral blood samples using ACK lysis solution (BioSource International, Rockville, MD). All samples were resuspended in RPMI 1640 medium containing 2.5% heat-inactivated FCS, 2-ME, L-glutamine, nonessential amino acids, HEPES, sodium pyruvate, penicillin, and streptomycin. Cells were stained with PE-labeled, tetramerized MHC molecules bearing Ags of interest. Drosophila S2 cells transfected with 2W1S-IA b monomers were a gift of Marc Jenkins at the University of Minnesota (28) . Secreted 2W1S-IA b was harvested from supernatants as described (29) but did not require additional biotinylation due to cotransfection of the BirA enzyme (James Moon and Marc Jenkins). Tetramerized 3K-IA b was prepared as described (29) . K b reagents were purified as described (30) and loaded with OVA (SIINFEKL) Ag prior to staining. Cells were coincubated with tetramer for 1 h at 37˚C prior to staining with surface Abs. Surface Abs were purchased from BioLegend (San Diego, CA) or eBioscience (San Diego, CA). For cytokine assays, cells were incubated for 3.5 h at 37˚C with 6 mg/ml brefeldin A in complete media as above. Cells were restimulated with 10 mg/ml 2W1S and SIINFEKL peptides, and following the incubation period, cells were fixed, permeabilized, and stained for intracellular cytokines as described (31) . DC were isolated from spleens in EHAA media (Invitrogen) containing DNAse (Worthington, Lakewood, NJ) and Collagenase D (Roche Diagnostics, Indianapolis, IN) as described (30) 
Mixed bone marrow chimeras
Recipient mice were lethally irradiated with 900 rad in the morning and grafted via the tail vein in the afternoon with 4 3 10 6 total T cell-depleted donor bone marrow cells suspended in 200 ml PBS. Bone marrow was depleted of T cells using magnetic removal of CD3 + cells (Miltenyi Biotec, Auburn, CA). Most mixed bone marrow chimeras were grafted at a ratio of 1:1, representing 2 3 10 6 cells from each of two donors. However, Ragdeficient bone marrow was enriched relative to competitor bone marrow 3:1 to enhance engraftment. Screening of recipients of B6.SJL and Ragrecombinase deficient (RagKO) bone marrow revealed that the 3:1 ratio was optimal for the generation of equal numbers of NK cells derived from each donor. Chimeric mice were rested a minimum of 12 wk before being immunized for experiments. Chimeric mice were fed tirmethoprim-sulfamethoxazole-containing chow (Harlan Teklad 6596; Harlan) for 6 wk following reconstitution to reduce the risk of bacterial infection, but were switched to standard chow (Harlan Teklad 2919; Harlan) well before immunization.
In vitro culture
Spleen cells were harvested as described above using DNAse and collagenase and cultured unfractionated at 1 3 10 6 cells/ml in 24-well, flatbottom plates. Cells were stimulated with 0.5 mg/ml anti-CD3ε (clone 2C11) in complete RPMI 1640 medium supplemented as above and with 10% FCS. In some cases, cells were incubated with 10 5 U/ml rIFN-a prepared as described (32) . At indicated time points, cells were harvested by washing plates with FACS buffer and stained as above.
Experimental and statistical analysis
Spleen cells were quantified on a Vi-Cell cell viability analyzer (Beckman Coulter). Cytometry samples were acquired on a CyAn ADP (DakoCytomation) using Summit acquisition software. Samples were analyzed using FlowJo software (Tree Star, Ashland, OR). In most cases, results from FlowJo analysis were imported into Prism (GraphPad, La Jolla, CA), and pairwise statistical analyses were made between samples using the Student t test. In vivo experiments used in this manuscript were completed independently at least twice with a minimum three individuals per group. In vitro experiments were completed independently at least three times.
Results
IFNaRKO mice have defective primary responses to combined polyI:C and CD40 stimulus
We have previously found that combined adjuvants polyI:C and an agonistic CD40 Ab (FGK4.5) synergistically promote CD4 + T cell responses (25, 26, 32) , whereas responses to either single agonist alone were as much as 10-fold lower than combined stimulus (26) . We also showed that polyI:C/CD40 stimulus promoted CD8 + T cell responses that were type I IFN dependent (25) . Whereas CD4 + T cell responses to immunizations containing polyI:C alone as an adjuvant are known to be dependent on type I IFN (12), we were interested in whether type I IFN was also required for promotion of CD4 + T cell responses in our polyI:C/CD40 adjuvant system.
We began by immunizing wild-type (WT) B6 mice and IFNaRKO B6 mice i.p. with both a CD4 + T cell Ag (the 2W1S Ag EAWGALANWAVDSA) and a CD8 + T cell Ag (whole OVA) in the presence of polyI:C and CD40 agonists (polyI:C/CD40). Immunization with polyI:C/CD40 promoted robust CD4 + T cell proliferative responses in WT mice (Fig. 1A, 1B) , as measured by the percentages (Fig. 1A) and numbers (Fig. 1B) + T cell proliferative responses to polyI:C/CD40 up to 10-fold in the spleen (Fig. 1A, 1B ) and peripheral blood ( Fig. 2A) . Thus, type I IFN signaling is critical for the synergistic effects of polyI:C/ CD40 for both CD4 + and CD8 + T cells and is not unique to any particular cell type.
We previously found that OX40L is required for optimal CD4 + T cell proliferation in WT mice (26) . We verified the role of OX40L in CD4 + T cell responses in both WT and IFNaRKOs by using the blocking Ab RM134L. Mice were injected i.p. with 250 mg of blocking Abs on days 21 and 0 relative to immunization with 2W1S and OVA Ags and polyI:C/CD40. Consistent with previous data (26), we found that CD4 + T cell responses in WT mice were reduced in the presence of RM134L blocking Ab (Fig.  1D ), whereas CD8 + T cell responses were unimpaired following OX40L blockade (26, 33 and data not shown). Somewhat to our surprise, the CD4 + T cell response in unblocked IFNaRKO mice were brought down even further in the presence of RM134L (Fig.  1D) . Again, CD8 + T cell responses in IFNaRKO mice were unaffected by RM134L (data not shown). Thus, even the remnant CD4 + T cell response in the IFNaRKO mice was largely dependent on OX40/OX40L interactions. Collectively, the data demonstrate the central importance of both type I IFN and OX40 in the generation of CD4 + T cell immunity following combined polyI:C/ CD40 immunization.
The defect in IFNaRKO mice is limited to primary but not secondary responses
We were interested to know whether the defect in primary CD4 + T cell responses in IFNaRKO mice led to impaired secondary responses. To assess the role of type I IFN in CD4 + T cell memory, we immunized B6 or IFNaRKO mice with 2W1S Ag and polyI:C/ CD40 as described above. Mice were followed by staining peripheral blood for the presence of Ag-specific CD4 + T cells at different time points. After allowing a recovery period of 40-70 d, the peripheral blood was monitored for the numbers of Ag specific memory cells as determined by tetramer staining (preboost). The mice were the rechallenged with a boosting dose of 2W1S and polyI:C/CD40, and secondary responses were measured 5 d later (postboost).
We reasoned that poor primary responses would predict poor secondary responses in IFNaRKO mice. To our surprise, we found that secondary proliferative responses in IFNaRKO mice were largely intact and almost equivalent to secondary responses in B6 mice ( Fig. 2A) . In particular, the fold expansion of 2W1S-specific CD4 + T cells from preboost levels to postboost levels was equivalent in IFNaRKO mice and B6 mice (Fig. 2C) . Other authors have noted that defects in type I IFN signaling during priming can lead to secondary responses with intact proliferation, but defective cytokine production (34) . In line with these previous observations (34), we found that secondary cytokine responses by CD4 + T cells in peripheral blood were generally reduced in IFNaRKO mice relative to WT mice (Fig. 2B) . However, in the spleen, the total number of cells producing IFN-g were more similar between WT mice and IFNaRKOs (not shown), and, in all cases, the fold expansion of cytokine-producing cells from pre-to postboost was similar between WT and IFNaRKOs (Fig. 2D) . Thus, our data indicate that secondary proliferation and cytokine production by CD4 + T cells are minimally dependent on type I IFN.
Curiously, we also found that WT and IFNaRKO mice responded equally well to secondary immunization, regardless of whether OX40L was blocked during the primary (Fig. 2E) or secondary (Fig. 2F) challenge. Blockade of OX40L during the primary response, although reducing the primary expansion of Agspecific CD4 + T cells, does not prevent the formation or response of memory CD4 + T cells (Fig. 2E) . Further, blockade of OX40L only after boosting vaccination has minimal impact on CD4 + T cell recall responses (Fig. 2F) . Broadly, we conclude from these data that OX40L plays an important role in determining the magnitude of the primary CD4 + T cell responses, but not the generation of memory or the response of the memory cells following rechallenge.
The IFNaR dependency of primary CD4 + T cell immune responses is T cell extrinsic
The fact that IFNaRKO CD4 + T cells could mount an effective secondary response suggested that the IFN dependency of the 
primary CD4
+ T cell response was not due to a requirement for IFNR expression on T cells. To more specifically address whether the effects of IFNaR deficiency are T cell intrinsic or extrinsic, we generated mixed bone marrow chimeras in lethally irradiated IFNaRKO recipients to isolate defects in type I IFN signaling to bone marrow-derived cells (Fig. 3A) . We used congenically marked CD45.1 + IFNaRKO bone marrow and mixed it 1:1 with WT B6 bone marrow (Fig. 3A) . We reasoned that, if IFNaR were required on responding T cells, we would observe a disproportionate response of the WT bone marrow-derived T cells as compared with the congenic, IFNaRKO bone marrow-derived T cells. Instead, we found that T cells derived from IFNaRKO bone marrow competed very well with WT bone marrow, if anything, responding better than the WT T cells (Fig. 3B) . This indicated that IFNaR was dispensable on responding CD4 + T cells to promote immune responses. Similar to previous reports of a CpG-based adjuvant system (13), our data suggested that the dependency of the polyI:C/CD40-elicited response on type I IFN must be due to a requirement for IFNR expression on the APCs (12). We therefore reconstituted irradiated IFNaRKO hosts with RagKO bone marrow mixed 3:1 (to enhance engraftment of RagKO marrow) with IFNaRKO bone marrow. The resulting host has T cells that are exclusively IFNaR deficient, but both WT and IFNaR-deficient APCs. As anticipated, the CD4 + T cell responses were rescued in these RagKO 3 IFNaRKO chimeras (Fig. 3C ). These data demonstrate that IFNaR is dispensable on responding CD4 + T cells and that cells derived from RagKO bone marrow are sufficient to restore IFNaR-dependent pathways in IFNaRKO mice.
We have previously shown that CD40 expression on innate cells was sufficient for the synergistic effects of agonistic anti-CD40 combined with polyI:C (26). Our finding that IFNaR expression was also sufficient on innate cells raised the question of whether CD40 and IFNaR were required on the same cells or whether + T cells of a separate experiment performed as in B. E, Mice were immunized with 2W1S peptide, and polyI: C/CD40 and OX40-OX40L interactions were blocked by injecting 250 mg of RM134L i.p. on days 21 and 0 relative to priming, as described in Materials and Methods. Sixty-seven days later, mice were rechallenged with Ag and polyI:C/CD40, and after 5 d, spleens were harvested and stained with 2W1S-IA b tetramer. Shown are percentages of Ag-specific CD4 + T cells in peripheral blood over time. F, Mice were primed with Ag and polyI:C/CD40 and reimmunized 70 d after priming with Ag and polyI:C/CD40. OX40L was blocked only during the secondary immunization by administering 250 mg of RM134L i.p. on days 21 and 0 relative to rechallenge. Shown are numbers of Ag-specific splenic CD4 + T cells 5 d following rechallenge. Data are representative of at least two independent experiments containing at least three mice per group. Statistics were calculated using Student t test and are pairwise comparisons to control unless otherwise indicated. **p , 0.01, ***p , 0.005. CD40 stimulus and polyI:C stimulus could work in trans for promotion of optimal CD4 + T cell responses to polyI:C/CD40. To determine whether CD40 and IFNaR were required on the same cells, we reconstituted lethally irradiated IFNaRKO mice with bone marrow derived from IFNaRKO.SJL mice alone, IFNaRKO. SJL and CD40KO bone marrow mixed 1:1, and IFNaRKO.SJL and B6 bone marrow mixed 1:1. We found that IFNaRKO.SJL and CD40KO bone marrow were not able to reconstitute responses in IFNaRKO recipients (Fig. 3D) , suggesting that both CD40 and IFNaR need to be expressed by the same APC in order for polyI: C/CD40 to promote robust CD4 + T cell immune responses. By extension, trans signals elaborated by polyI:C/CD40 are not sufficient for the combined effects of both agonists.
IFNaRKO DC demonstrate defective activation in response to polyI:C and CD40 stimulus
The data thus far indicate that the dependency of the CD4 + T cell response elicited by combined polyI:C/CD40 immunization must be due to the action of IFN on the APC. Other authors have also shown that DCs can be regulated in an intrinsic IFNaR-dependent manner (8, 12) . To understand how IFNaR deficiency might affect DC activation, we immunized B6 and IFNaRKO mice in one footpad with fluorescent OVA Ag and polyI:C/CD40 stimulus and isolated DCs from the ipsilateral and contralateral popliteal lymph nodes 18-24 h later. FACS histograms revealed that IFNaRKO DCs (Fig. 4A) had relative defects in Ag uptake, MHC-II expression, CD69 expression, and CCR7 expression compared with WT mice (Fig. 4A) . Importantly, DCs from IFNaRKO mice did upregulate these molecules relative to cells from contralateral nodes in WT mice (Fig. 4A, shaded area) , suggesting that DC activation was not completely absent in IFNaRKO mice, but was impaired.
Given the established importance of OX40/OX40L signaling in mediating the CD4 + T cell response to combined polyIC/CD40 immunization ( Fig. 1) (26) , we were interested to know whether expression of OX40L on activated DCs was also influenced by the presence or absence of IFN. We chose to focus on CD8 + DCs, as OX40L expression is more pronounced on this subset, and we have found that CD8 + DC OX40L expression correlates to CD4 + T cell responses (26) . We found that both OX40L expression and MHC-II expression on CD8 + DCs were reduced at multiple time points in IFNaRKOs relative to WT mice (Fig. 4B) .
Although the loss of DC OX40L expression was not absolute in the IFNaRKOs (as evidenced by the fact that OX40L blockade can still reduce the residual T cell response in these hosts) (Fig.  1D) , the majority of OX40L expression appeared to be IFN dependent (Fig. 4B) . These data suggested that the introduction rIFN-a might be sufficient to promote DC OX40L expression. We harvested naive splenocytes and stained them directly (Fig. 4C) or cultured them in the presence of anti-CD3 (2C11), rIFN-a, or anti-CD3 and rIFN-a. Intriguingly, anti-CD3 alone and anti-CD3 with IFN-a did not lead to appreciable expression of OX40L in these cultures (Fig. 4C) . However, administration of rIFN-a alone was sufficient to massively upregulate OX40L expression on cultured DCs (Fig. 4C) . Furthermore, DCs increased expression of CD70 in the presence of rIFN-a (Fig. 4C) , regardless of the presence of anti-CD3.
It was interesting that IFN-a alone, but not IFN-a with anti-CD3, led to upregulation of OX40L on cultured DCs (Fig. 4C) . The Ab used to detect OX40L expression, RM134L, is also useful for blockade of OX40L-OX40 interactions (26) . We hypothesized that activation of responding T cells in the presence of anti-CD3 and rIFN-a may have led to upregulation of OX40, which, in turn, might prevent detection of OX40L on the DCs, either by downmodulating OX40L expression or directly interfering with Ab binding to OX40L. We therefore assessed the expression of OX40 on responding CD4 + T cells. We found that OX40 expression was high in the presence of anti-CD3 alone 6 rIFN-a, but not on naive cells or on cells stimulated with IFN-a alone (Fig. 4D) . This result is consistent with the finding that, in vivo, priming of CD4 + T cells does not require IFNaR on the cells themselves. Similarly, expression of another TNFR, CD27, was high on CD4 + T cells under all conditions, but appeared to increase in the presence of anti-CD3 (Fig. 4D) . This suggests that regulation of DC TNF ligand expression could be a direct consequence of type I IFN, but regulation of the receptors on responding CD4 + T cells is likely to be a consequence of CD3-mediated TCR stimulus.
OX40 receptor stimulation rescues CD4 + T cell responses in IFNaRKO mice
As OX40L signals were required for optimal CD4 + T cell priming, but defective in IFNaRKO mice, we hypothesized that restoration of signaling through OX40 might restore CD4 + T cell responses in IFNaRKOs. We therefore administered single doses of the OX40-agonistic Ab, OX86 (35, 36) , to WT and IFNaRKO mice coin- The Journal of Immunologycident with immunization by Ag and polyI:C/CD40. We found that agonistic OX40 Ab largely enhanced CD4 + T cell responses (Fig. 5A) , but not CD8 + T cell responses (Fig. 5B) , in WT and IFNaRKO mice. These data confirmed a unique role for OX40 in CD4 + T cell, but not CD8 + T cell, priming, which is reflected by the literature (37) . In all cases, cytokine production by CD4 + and CD8 + T cells reflected the tetramer responses shown in this study (not shown). Thus, augmentation of OX40-OX40L signals in IFNaRKO mice can substantially enhance CD4 + T cell, but not CD8 + T cell primary responses.
Discussion
Collectively, our data contribute to the growing literature of the influence of type I IFN on adaptive immunity by adding a critical role for type I IFN in DC OX40L expression and subsequent stimulation CD4 + T cells through OX40. In addition, our data challenge the paradigm that direct stimulation of T cells by IFN is required for their capacity to respond to primary challenge. Several authors have written on the role of direct type I IFN signals for T cell immunity (12, 20, (38) (39) (40) and in particular the role of type I IFN in Th1-type immune responses is controversial (39) . However, we could find no evidence that the Th1 phenotype of responding CD4 + T cells was different between WT and IFNaRKO mice. Rather, we noted reduced responses across the board in IFNaRKOs relative to B6 controls in both proliferation and cytokine production, suggesting a defect in CD4 + T cell proliferation, but not necessarily differentiation. Furthermore, using a mixed bone marrow chimeric system, we were able to show that absence of IFNaR on responding CD4 + T cells does not disfavor their participation in primary immune responses with competing WT cells. In fact, we show isolated IFNaRKO CD4 + T cells in a system without any cells able to sense type I IFN, save for bone-marrow-derived, Rag-independent cells, have the capacity to mount effective primary immune responses to IFNdependent stimuli. Granted, the outcomes we measure, such as CD4 + T cell proliferation, are different from the outcomes others have measured, such as Ab production (38) or CD8 + T cell differentiation (20) . Nevertheless, our data support a minimal role for type I IFN signaling to CD4 + T cells during primary responses. We note also that, in our dual-adjuvant system, it is unlikely that CD40 stimulus is rescuing IFN-dependent responses. We have shown that CD40 is dispensable on responding CD4 + T cells in the setting of polyI:C/CD40 stimulus (26) , and we show in this study that IFNaR and CD40 must be on the same cells to promote synergistic immune responses. This is consistent with our previous data as well, in which we have shown that CD40 is sufficient on innate cells for polyI:C/CD40-induced priming (26) . Although CD40 agonist by itself is a sufficient adjuvant to initiate adaptive immune responses (41) and is not known to be dependent on type I IFNs, it is interesting that the phenotype of IFNaRKO mice dominates to limit expansion of CD4 + T cells dramatically compared with WT mice. It is possible, however, that CD40 agonism may reverse some of the defects in CD4 + T cell responses that other authors have observed in IFNaRKO mice (17, 21) . If true, taken with our previous data that CD40 is necessary on innate cells (26) , our data would suggest that CD40 agonism acts indirectly, through APCs, to rescue CD4 + T cell memory in IFNaRKO mice.
We have previously shown that rIFN-a will directly synergize with agonistic anti-CD40 Ab to promote CD8 + T cell responses when combined together (32) . However, we have not been able to show that rIFN-a would synergize with anti-CD40 to promote CD4 + T cell responses (data not shown). This implies that although IFNaR is indispensable for the effects of polyI:C/CD40 immunization, IFN-a itself is not sufficient to synergize with CD40 agonists for CD4 + T cells. We account for this by noting that CD4 + and CD8 + T cells in this setting require slightly different priming conditions (26) and that these could be affected by the dose of recombinant IFNa used. It is possible that CD4 + and CD8 + T cell priming is initiated by different APC subsets (42, 43) , and these might have different sensitivities to rIFN-a. Alternatively, IFN-a is one of many types of type I IFN, all of which require the IFNaR to function (44) , and any of these may differentially impact Ag presentation to CD4 + and CD8 + T cells, either by having variable effects on different APC subsets or by directly impacting presentation through MHC-II or MHC-I in an paralog-dependent manner.
A larger question raised by these data concerns our findings that both IFN and OX40 are dispensable for secondary CD4 + T cell responses but required for primary responses. This disagrees with previous observations (17, 21, 23) and is particularly interesting given the finding that, in the case of lymphocytic choriomeningitis viral infection, survival of CD4 + T cells is dependent on cellintrinsic type I IFN signaling (21) . In contrast, our bone marrow chimera suggests that intrinsic roles for type I IFN are dispensable and that the primary role for IFN in CD4 + T cell responses is T cell extrinsic. Consistent with this, cell-intrinsic type I IFN signaling was not required for CD4 + T cell responses to bacterial infection (21) , whereas studies conflict with regard to the necessity for direct IFN signaling to T cells in response to vaccinia virus challenge (40, 45) . There are a number of non-mutually exclusive ways to reconcile our data with these findings. One is that our dual-agonist immunization system exploits a pathway that permits CD4 + T cell survival similar to the result found for bacterial infection (discussed above) (21) . Another possibility is that, during lymphotrophic viral infection such as lymphocytic choriomeningitis virus, the inability to respond to IFN signals leads to killing of CD4 + T cells by direct infection. Third, as has been previously suggested (40) , the inflammatory environment present during the initial stimulation of the T cells may dictate the degree of dependence or independence of direct IFN signaling into the T cells. A final possibility is that aberrant IFN responses by CD4 + T cells in infected tissue leads to lysis by NK cells or CTL.
Our data show that the causes of poor primary responses that are attributable to IFNaRKO mice are not as relevant for secondary responses as they are for primary responses. To some extent, this is not surprising, as primary and memory CD4 + T cells are qualitatively different from each other (46, 47) , and our work adds to this body of literature. However, our data showing memory responses either in the absence of type I IFN signaling or during OX40L blockade begs the question of how WT levels of secondary T cell expansion can occur after such a compromised primary burst size. One explanation is that larger clonal burst sizes lead to shorter t 1/2 of daughter progeny, which is an extrapolation of recent data showing that population size of CD4 + T cells is a determinant of survival (48) . An alternative, but not mutually exclusive, explanation for these data is that a population of T cells with high avidity for Ag, which is thought to be important for CD4 + T cell memory formation (47) , is able to become activated in WT and IFNaRKO mice regardless of costimulation. Thus, addition of extra costimulation and Ag presentation in WT mice in this model might provide activation and recruitment of more lower avidity cells, increasing the primary burst size but not the memory pool. Similarly, it is possible that memory formation is facilitated by a minimal threshold of activation beyond which extra proliferation yields extra effector cells, but not necessarily more memory. Thus, type I IFN and OX40L costimulation may promote effector cell generation beyond what is required for memory formation, and the blockade or loss of these signaling pathways reduces clonal burst size by reducing effectors. All possibilities outlined above are validated for OX40 by recent data (49, 50) .
Although we observed what appears to be a causal association among CD4 + T cell priming, IFN, and DC OX40L expression, there are likely other defects in APC function that contribute to the IFN dependency of the T cell response. DC activation (10, 12, 13) , trafficking (8) , and Ag presentation (9) are all impaired in the absence of type I IFN. We have confirmed many of these defects in our system by observing reduced Ag uptake, expression of MHC-II, CD69, CCR7, CD80, and CD86 (Fig. 4 and data not shown), all of which contribute to poor CD4 + T cell priming in the absence of IFN. In particular, we show that stimulation by anti-CD3 Abs through the TCR is important in vitro for OX40 upregulation on CD4 + T cells. We extrapolate that impaired TCR stimulus might impair CD4 + T cell competence for OX40 stimulus. This explains why IFNaRKO mice, in which MHC-II expression is impaired, are not completely rescued by OX86 to the level of WT mice treated with OX86. Nevertheless, the connection we make to OX40L demonstrates that defects in IFNaR signaling can have very concrete molecular consequences for the ability of DCs to prime CD4 + T cells and that these defects may be partially reversed by agonist treatment of key pathways absent in IFNaRKOs.
Collectively, our data contribute to the growing body of evidence that the induction of type I IFN in a vaccine setting can have a powerful influence on the generation of cellular responses largely through an influence on APC function. These data imply that the application of IFN or IFN-inducing modalities to the generation of T cell immunity will need to take into consideration the fact that the The Journal of Immunologyprimary function of IFN would be early in the generation of the response and that continued application of IFN beyond the window of necessary APC function will likely only be self-limiting. Thus, although the primary clinical regimen of chronic IFN dosing is appropriate to capitalize on the direct antiviral and cytostatic properties of IFN signaling, the use of IFN as a therapeutic intervention to augment the adaptive response will likely need to consider a shorter course of IFN treatment. Our data indicate that OX40-OX40L interactions will be a critical component by which type I IFN elicits CD4 + T cell responses with hopeful protective and/or therapeutic potential.
